DrugPatentWatch Database Preview
CLINICAL TRIALS PROFILE FOR LANSOPRAZOLE
Clinical Trials for Lansoprazole
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT00149084 | Tailored Treatment of H. Pylori Infection Based Polymorphisms of CYP2C19 and 23S rRNA of H. Pylori | Unknown status | Yokoyama Foundation for Clinical Pharmacology | Phase 3 | The eradication rate of the standard H. pylori eradication therapy (such as the triple therapy with a proton pump inhibitor [PPI], amoxicillin and clarithromycin) depends on bacterial susceptibility to clarithromycin and genotypes of CYP2C19 in patients. The investigators intend to investigate whether the tailored therapy based on the two above-mentioned factors increases the cure rate of the initial eradication therapy. |
| NCT00149084 | Tailored Treatment of H. Pylori Infection Based Polymorphisms of CYP2C19 and 23S rRNA of H. Pylori | Unknown status | Hamamatsu University | Phase 3 | The eradication rate of the standard H. pylori eradication therapy (such as the triple therapy with a proton pump inhibitor [PPI], amoxicillin and clarithromycin) depends on bacterial susceptibility to clarithromycin and genotypes of CYP2C19 in patients. The investigators intend to investigate whether the tailored therapy based on the two above-mentioned factors increases the cure rate of the initial eradication therapy. |
| NCT00174928 | A Study to Evaluate the Effect of Lansoprazole on Hospitalized Neonates With Gastroesophageal Reflux Disease | Completed | Takeda | Phase 1 | The purpose of this study is to understand how quickly lansoprazole, once daily (QD), improves feeding in premature babies or babies less than 28 days of age. |
| NCT00175032 | A Comparison of Safety and Treatment in Subjects With Osteoarthritis Taking Low Dose Aspirin | Completed | Takeda | Phase 3 | The purpose of this study is to compare the gastroduodenal ulceration rate, gastrointestinal complication rate and non-steroidal anti-inflammatory drug-associated dyspepsia between lansoprazole, naproxen and celecoxib, taken once daily (QD) or twice daily (BID), in participants with osteoarthritis taking low dose aspirin. |
| NCT00175045 | Intravenous vs Oral Lansoprazole on Gastric Acid Secretion in Subjects With Erosive Esophagitis | Completed | Takeda | Phase 2 | The purpose of this study was to compare the pharmacodynamics of intravenous (IV) lansoprazole to oral lansoprazole capsules, once daily (QD), in participants with erosive esophagitis. |
| NCT00204373 | Treatment of Zollinger-Ellison Syndrome With Prevacid | Completed | Takeda Pharmaceuticals North America, Inc. | Phase 4 | The purpose of this study is to study the safety and efficacy of high dose Prevacid in the long-term treatment of patients who secrete abnormally large amounts of gastric acid. |
| NCT00204373 | Treatment of Zollinger-Ellison Syndrome With Prevacid | Completed | Charles Mel Wilcox, MD | Phase 4 | The purpose of this study is to study the safety and efficacy of high dose Prevacid in the long-term treatment of patients who secrete abnormally large amounts of gastric acid. |
| Trial ID | Title | Status | Sponsor | Phase | Summary |
Clinical Trial Conditions for Lansoprazole
Condition Name
Condition MeSH
Clinical Trial Locations for Lansoprazole
Trials by Country
Clinical Trial Progress for Lansoprazole
Clinical Trial Phase
Clinical Trial Sponsors for Lansoprazole
Sponsor Name
